RAB7A and familial pancreatic carcinoma: In addition, RAB7A was significantly more highly expressed in patients with pancreatic cancer in the progressive disease (PD) group than in those in the stable disease (SD) and complete response (CR) groups and not significantly different from those in the partial response (PR) group in terms of the outcome of initial treatment (Fig. 7B–G).